Navigation Links
EUCODIS Bioscience Appoints Thomas Fischer as New CEO
Date:12/7/2009

VIENNA, Austria, December 7 /PRNewswire/ -- EUCODIS Bioscience, a company developing, customizing, manufacturing, and marketing enzymes for the chemical industry, announced today that it has appointed Mr Thomas Fischer, currently CFO, as new CEO of the Company. Going forward, EUCODIS Bioscience' sole focus will be to provide high-performance enzymes to customers, capitalizing on the Company's experience in commercial enzyme development and on its proven technology of "in vivo recombination".

In line with this move EUCODIS Bioscience will spin out its French research subsidiary in a management buy-in lead by Rudy Pandjaitan, PhD, previously CEO of EUCODIS Bioscience.

Dr. Pandjaitan will acquire a majority stake in the new entity. Under his leadership the new entity will develop next-generation applications of "in vivo recombination". EUCODIS Bioscience will retain a strategic share in its former subsidiary.

"White Biotechnology, or enzyme-based products and manufacturing, is a 100 billion Euro market, and EUCODIS Bioscience is well positioned to exploit the huge commercial potential of this business", said Thomas Fischer, CEO of EUCODIS Bioscience. "It was under Rudy's leadership that the Company has developed into this position, and we are pleased that he will continue to actively support EUCODIS Bioscience in the area of business development as a consultant."

"EUCODIS Bioscience' technology is a powerful and proven tool for the creation of novel enzymes", said Dr. Pandjaitan. "Even more fascinating, in vivo recombination may also be used in synthetic biology, generating DNA strands of more than 10,000 base pairs on a routine basis. It is our vision that in vivo recombination will enable the creation of novel pathways and even whole genomes, providing a key technology for the 'cellular factory' of the future."

"In vivo recombination" is EUCODIS Bioscience' proprietary, patent-protected technology for the development of industrial enzymes with novel properties.

About EUCODIS Bioscience

EUCODIS Bioscience GmbH develops, customizes, manufactures, and markets industrial enzymes.

EUCODIS Bioscience' products help customers in the chemical, pharmaceutical, and food and feed industries to make manufacturing processes more efficient and cleaner, and to generate products with superior properties.

EUCODIS Bioscience originally focused on developing enzymes for industrial partners, including GlaxoSmithKline, Henkel, and Lohmann Animal Health. Since 2009, the Company also markets its own products.

Led by an experienced management team, EUCODIS Bioscience is backed by Austrian and German institutional venture capital funds, founders, and private investors. The Company is headquartered in Austria, Europe, with a subsidiary in Germany.

    For more information, please visit http://www.eucodisbioscience.com

    Company contact EUCODIS Bioscience:
    Thomas Fischer, MBA
    CEO
    EUCODIS Bioscience
    Campus Vienna Biocenter II
    Viehmarktgasse 2 a/ 2 OG
    A-1030 Vienna
    AUSTRIA
    +43-1-8900804
    office@eucodisbioscience.com

    Media contact EUCODIS Bioscience:
    Frank Butschbacher
    Investor Relations & Communications
    http://www.butschbacher.net
    +43-650-7844940
    office@butschbacher.net

SOURCE EUCODIS Bioscience


'/>"/>
SOURCE EUCODIS Bioscience
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. EUCODIS Bioscience to Explore Novel Enzymatic Activities in Antarctic Bacteria Library From Bio Sidus
2. EUCODIS Bioscience Launches Lipase Portfolio
3. EUCODIS Bioscience Launches Beta-Lactamase for Antibiotics and Diagnostics Industries
4. EUCODIS Bioscience Signs Research Agreement With Genencor
5. EUCODIS Bioscience and Lohmann Animal Health Announce Achievement of Major Development Milestone
6. EUCODIS Bioscience Appoints Thomas Fischer as Chief Financial Officer
7. Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc.
8. Dow AgroSciences, Agrisoma Biosciences Announce Research and Commercial License Option Agreement for Agricultural Crops
9. Ardea Biosciences to Present at the Piper Jaffray 21st Annual Health Care Conference
10. YM BIOSCIENCES REPORTS FIRST PATIENT IN PHASE I/II TRIAL OF JAK1/JAK2 INHIBITOR, CYT387 ENROLLED BY CYTOPIA
11. American BioSciences Rebuts Misleading Statements Made by Hungarian Competitor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... IA (PRWEB) , ... March 01, 2017 , ... ... announce finalization of an agreement that formalizes their clinical research partnership. Effective ... McFarland Clinic. This collaboration brings an increased opportunity for McFarland Clinic patients and ...
(Date:3/1/2017)... March 1, 2017  Elizabeth Young and Joshua ... the George Washington University,s Health Workforce Speaker series. ... Rosenthal will be speaking on March 9, 2017 ... Washington, DC at 12:00pm. ... invites nationally renowned speakers to examine new workforce configurations, ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... Inc. (Newark, DE) have formed a strategic partnership to develop and market ... renewable energy laboratories. These automated testing solutions will save analysis time and ...
(Date:2/28/2017)... and REYKJAVIK, Iceland , Feb. 28, ... group company and the contract genomics organization enabling precision ... Hannes Smarason has been appointed as the company,s chief executive ... and Alex Fowkes have been named chief ... "WuXi NextCODE is executing on its vision to enable anyone ...
Breaking Biology Technology:
(Date:2/21/2017)... PORTLAND, Ore. , Feb. 22, 2017 /PRNewswire/ ... of Companies (Avamere Health Services, Infinity Rehab, Signature Hospice, ... study that will apply the power of IBM cognitive ... and health centers. By analyzing data streaming from sensors ... into physical and environmental conditions, and obtain deeper learnings ...
(Date:2/16/2017)... Feb. 16, 2017  Genos, a community for ... it has received Laboratory Accreditation from the College ... presented to laboratories that meet stringent requirements around ... rigorous processes. "Genos is committed to ... practices. We,re honored to be receiving CAP accreditation," ...
(Date:2/13/2017)... SAN FRANCISCO , Feb. 13, 2017 /PRNewswire/ ... a centralized platform that is designed to enhance ... the latest release in the RSA Fraud & ... to enable organizations to leverage additional insights from ... anti-fraud tools to better protect their customers from ...
Breaking Biology News(10 mins):